KLOW Blend (GHK-Cu + TB-500 + BPC-157 + KPV)

KLOW Blend is a multi-peptide formulation combining GHK-Cu(50mg), TB-500(10mg), BPC-157(10mg), and KPV(10mg). It is studied for its potential synergistic effects in reducing inflammation, supporting healing, and promoting skin and tissue health \n \nKLOW Blend brings together four peptides that have each been independently studied across regenerative biology, inflammatory pathway, and extracellular matrix research — and each operates through a mechanistically distinct signaling route. \n \nGHK-Cu, the naturally occurring copper tripeptide first isolated from human plasma by Pickart in 1973, is studied for copper-dependent collagen synthesis signaling, MMP/TIMP matrix remodeling balance, and keratinocyte migration activity in skin and connective tissue preparations. BPC-157, a synthetic pentadecapeptide, contributes VEGF-dependent angiogenic signaling through VEGFR2 and FAK phosphorylation pathways. TB-500, the synthetic Thymosin Beta-4 analog, adds VEGF-independent vascular signaling via integrin αvβ3 and Akt-eNOS activation, alongside actin-mediated cell migration facilitation. \n \nKPV — the fourth and newest addition to this formulation — is a tripeptide derived from the C-terminal sequence of α-MSH. Its primary research interest lies in its ability to enter cells via PepT1, a peptide transporter expressed in intestinal epithelial, immune, and mucosal cell preparations, where it directly inhibits NF-κB nuclear translocation and downstream pro-inflammatory cytokine expression. \n \nKLOW Blend addresses inflammatory signaling through two separate pathway entry points simultaneously.